Obsidian Therapeutics
- Market cap
- 815.40M
- P/E (TTM)i
- 20.31
- P/Bi
- 2.32
- EPSi
- 0.65
- Div yieldi
- 0.00%
- 52W posi
- 3%
Anonymous reader poll. Unscientific, not investment advice.
About Obsidian Therapeutics
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- Employees
- 71
- Fiscal year end
- 12-31
- Website
- obsidiantx.com
Company profile
- Exchange
- US
- Symbol
- OBX
- Market-cap rank
- #3403
- Market cap
- 815.40M
- Float cap
- 699.00M
- Shares out
- 61.77M
- Float shares
- 52.95M
Sectors & themes
Quote time 2026-10-08 08:11:02 · For reference only, not investment advice and not tailored to your situation.